[1]. Wang C#, Zhang W#, He Y#, Gao Z, Liu L, Yu S, Hu Y, Wang S, Zhao C, Li H, Shi J, Zhou W, Li F, Yue H, Li Y*, Wei W*, Ma G*, Ma D*. Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects. Nat Nanotechnol. 2021 Dec;16(12):1413-1423.（IF=34.9）
[2]. Xie X#, Hu Y#, Ye T#, Chen Y, Zhou L, Li F, Xi X, Wang S, He Y, Gao X, Wei W*, Ma G*, Li Y*. Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen. Nat Biomed Eng. 2021 May;5(5):414-428.（IF=26.6）
[3]. Huang Y*, Qin Y, He Y, Qiu D, Zheng Y, Wei J, Zhang L, Yang DH*, Li Y*. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies. Drug Resist Updat. 2024 May;74:101082.（IF=21.7）
[4]. Wang H#, Guan T#, Hu R#, Huang Z, Liang Z, Lin X, Qiu Y, Liao P, Guo X, Ke Y, Zhang H*, Ou C*, Li Y*. Targeting KAT7 inhibits the progression of colorectal cancer. Theranostics. 2025 Jan 2;15(4):1478-1495.（IF=13.3）
[5]. Xia X#, Yang Z#, Lu Q#, Liu Z, Wang L, Du J, Li Y*, Yang DH*, Wu S*. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer. 2024 Aug 26;23(1):175.（IF=33.9）
[6]. Zhang H#, Wang H#, Hu Y#, Gao Y, Chen J, Meng Y, Qiu Y, Hu R, Liao P, Li M, He Y, Liang Z, Xie X*, Li Y*. Targeting PARP14 with lomitapide suppresses drug resistance through the activation of DRP1-induced mitophagy in multiple myeloma. Cancer Lett. 2024 Apr 28;588:216802.（IF=10.1）
[7]. Tu S#, Zhou L#, Huang R, Zhou X, Yang J, He Y, Hu Y, Zhang H, Xie X, Li Y*. Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients. Am J Hematol. 2024 Jul;99(7):1437-1440.（IF=9.9）
[8]. Huang S#, Wang X#, Wang Y#, Wang Y#, Fang C, Wang Y, Chen S, Chen R, Lei T, Zhang Y, Xu X*, Li Y*. Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies. Mol Cancer. 2023 May 6;22(1):80.（IF=33.9）
[9]. Wu X#, Jiao Z#, Zhang J, Li F, Li Y*. Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier. J Nanobiotechnology. 2023 Apr 11;21(1):126.（IF=12.6）
[10]. Qiu Y#, Liao P#, Wang H#, Chen J, Hu Y, Hu R, Zhang H, Li Z, Cao M, Yang Y, Li M, Xie X*, Li Y*. Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment. Int J Biol Sci. 2023 Sep 18;19(15):4948-4966.（IF=10.0）
[11]. Wang H#, Qiu Y#, Zhang H#, Chang N, Hu Y, Chen J, Hu R, Liao P, Li Z, Yang Y, Cen Q, Ding X, Li M, Xie X*, Li Y*. Histone acetylation by HBO1 (KAT7) activates Wnt/β-catenin signaling to promote leukemogenesis in B-cell acute lymphoblastic leukemia. Cell Death Dis. 2023 Aug 4;14(8):498.（IF=9.6）
[12]. Xu B#, Zhou Z#, Wen Y, Li Z, Huang Z*, Li Y*. The immunometabolic landscape of the bone marrow microenvironment in acute myeloid leukemia. Exp Hematol Oncol. 2022 Oct 28;11(1):81.（IF=13.5）
[13]. Xiao X#, Huang S#, Chen S, Wang Y, Sun Q, Xu X*, Li Y*. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021 Nov 18;40(1):367.（IF=12.8）
[14]. Qiu Y#, Chen T#, Hu R#, Zhu R, Li C, Ruan Y, Xie X*, Li Y*. Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. Biomark Res. 2021 Oct 9;9(1):72.（IF=11.5）
[15]. Li M#, Yang J#, Zhang L#, Tu S, Zhou X, Tan Z, Zhou W*, He Y*, Li Y*. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. J Exp Clin Cancer Res. 2019 May 22. (IF=12.8）
[16]. Chen Y#, Xie X#, Wu A, Wang L, Hu Y, Zhang H, Li Y*. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. J Exp Clin Cancer Res. 2018. 37(1):12. (IF=12.8）
[17]. Chen J#, Cen Q#, Hu R#, Qiu Y, Zhang H, Wang H, Hu Y*, Xie X*, Li Y*. Administration of lipid nanoparticle-encapsulated mRNA encoding CCR7, CXCL16 and GITRL effectively mobilizes antitumor T cell immunity. Int J Biol Macromol. 2025 Jul;318(Pt 1):144766.（IF=8.5）
[18]. Wu S#, Wei Y#, Qiu Y#, Ai K#, Chen M, Wang H, Zhang H, Cen Q, Liao P, Ding X, Xie X*, Li Y*. Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt/β-catenin pathway. J Transl Med. 2025 Apr 30;23(1):494.（IF=7.5）
[19]. Wang L#, Yue C, Zhou X, Yang J, Jin B, Wang B, Huang M, Chen H, Zhou L, Tu S, Li Y*. Efficacy and safety of chimeric antigen receptor T cell therapy combined with zanubrutinib in the treatment of relapsed/refractory diffuse large B-cell lymphoma. Chin Med J (Engl). 2025 Mar 20;138(6):748-750.（IF=7.3）
[20]. Tu S#, Li P#, Mei H#, Liu Y#, Hu Y, Liu P, Zou D, Niu T, Xu K, Wang L, Yang J, Zhao M, Huang X, Wang J, Hu Y, Zhao W, Wu D, Ma J, Qian W, Han W*, Li Y*, Liang A*. Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma. Chin Med J (Engl). 2025 Aug 20;138(16):1894-1896.（IF=7.3）
[21]. Zhang H#, Chen J#, Meng Y#, Cen Q, Wang H, Ding X, Ai K, Yang Y, Gao Y, Qiu Y, Hu Y, Li M*, He Y*, Li Y*. Overexpression of Pin1 regulated by TOP2A, which subsequently stabilizes Pyk2 to promote bortezomib resistance in multiple myeloma. Cancer Gene Ther. 2025 Jan;32(1):22-37.（IF=5.0）
[22]. Cen Q#, Chen J, Guo J, Chen M, Wang H, Wu S, Zhang H, Xie X*, Li Y*. CLPs-miR-103a-2-5p inhibits proliferation and promotes cell apoptosis in AML cells by targeting LILRB3 and Nrf2/HO-1 axis, regulating CD8 + T cell response. J Transl Med. 2024 Mar 14;22(1):278.（IF=7.5）
[23]. Huang R#, He H#, Xu X#, Lin X#, Dong Y, Wang X, Jiang F, Huang P, Mo S, Huang Z, Wang Y, Tao H, Zheng Y, Wu M, Yang C, Zheng Z, Zhao Y*, Zhang Y*, Li Y*. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis. Cancer. 2024 Jul 15;130(14):2472-2481.（IF=5.1）
[24]. Xie X#, Zhang W#, Zhou X, Xu B, Wang H, Qiu Y, Hu Y, Guo B, Ye Z, Hu L, Zhang H, Li Y*, Bai X*. Low doses of IFN-γmaintain self-renewal of leukemia stem cells in acute myeloid leukemia. Oncogene. 2023 Dec;42(50):3657-3669.（IF=7.3）
[25]. Xie X#, Zhang W#, Xiao M, Wei T, Qiu Y, Qiu J, Wang H, Qiu Z, Zhang S, Pan Y, Mao L, Li Y, Guo B, Yang W, Hu Y, Hu S, Gong Y, Yang J, Xiao G*, Zhang Y*, Bai X*. TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice. Blood. 2023 Jun 29;141(26):3184-3198.（IF=23.1）
[26]. Wang Y#, Morishima T#, Sezaki M, Sato R, Nakato G, Fukuda S, Kobiyama K, Ishii KJ, Li Y*, Takizawa H*. Akkermansia muciniphila induces slow extramedullary hematopoiesis via cooperative IL-1R/TLR signals. EMBO Rep. 2023 Dec 6;24(12):e57485.（IF=6.2）
[27]. Qiu Y#, Xu B#, Feng J#, Wang C, Chen Y, He Y, Xie X*, Li Y*. Loss of EPS8 sensitizes non-small-cell lung carcinoma to chemotherapy-induced DNA damage. Cancer Gene Ther. 2023 Jul;30(7):997-1006.（IF=5.0）
[28]. Zhao K#, Lin R#, Fan Z#, Chen X#, Wang Y#, Huang F, Xu N, Zhang X, Zhang X, Xuan L, Wang S, Lin D, Deng L, Nie D, Weng J, Li Y, Zhang X, Li Y, Xiang AP*, Liu Q*. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022 Mar 7;15(1):22.（IF=40.4）
[29]. Li KX#, Wu HY#, Pan WY, Guo MQ, Qiu DZ, He YJ, Li YH, Yang DH*, Huang YX*. A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib. Mol Cancer. 2022 Mar 4;21(1):66.（IF=33.9）
[30]. Chen S#, Zhang Y#, Fang C#, Zhang N, Wang Y, Chen R, Li Y*, Tu S*. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022 Nov;179:103807.（IF=5.6）
[31]. Han S#, Zhou L#, Chen Y, Zhou X, Guo Z, Yang J, Jin B, Liu Y, Chang LJ, Li Y*, Tu S*. The role of allogeneic haematopoietic cell transplantation as consolidation after anti-CD19 CAR-T cell therapy in adults with relapsed/refractory acute lymphoblastic leukaemia: a prospective cohort study. Bone Marrow Transplant. 2022 Mar;57(3):513-516.（IF=5.2）
[32]. Wu HY#, Li KX, Pan WY, Guo MQ, Qiu DZ, He YJ, Li YH, Huang YX*. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway. Int Immunopharmacol. 2022 Mar;104:108497.（IF=4.7）
[33]. Xiao M#, Zhang W#, Liu W, Mao L, Yang J, Hu L, Zhang S, Zheng Y, Liu A, Song Q, Li Y, Xiao G, Zou Z*, Bai X*. Osteocytes regulate neutrophil development through IL-19: a potent cytokine for neutropenia treatment. Blood. 2021 Jun 24;137(25):3533-3547.（IF=23.1）
[34]. Xu B#, Hu R#, Liang Z, Chen T, Chen J, Hu Y, Jiang Y*, Li Y*. Metabolic regulation of the bone marrow microenvironment in leukemia. Blood Rev. 2021 Jul;48:100786.（IF=5.823）
[35]. Chang YJ#, Wu DP#, Lai YR#, Liu QF, Sun YQ, Hu J, Hu Y, Zhou JF, Li J, Wang SQ, Li W, Du X, Lin DJ, Ren HY, Chen FP, Li YH, Zhang X, Huang H, Song YP, Jiang M, Hu JD, Liang YM, Wang JB, Xiao Y, Huang XJ*. Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. J Clin Oncol. 2020 Oct 10;38(29):3367-3376.（IF=41.9）
[36]. Chen Y#, Xie X#, Wang C#, Hu Y, Zhang H, Zhang L, Tu S, He Y, Li Y*. Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities. Cell Death Dis. 2020 Sep 1;11(8):712.（IF=6.304）
[37]. Wang Y#, Zhang L#, Tang X, Luo J, Tu Z, Jiang K, Ren X, Xu F, Chan S, Li Y*, Zhang Z*, Ding K*. GZD824 as a FLT3, FGFR1 and PDGFRαInhibitor Against Leukemia In Vitro and In Vivo. Transl Oncol. 2020 Apr;13(4):100766.（IF=3.558）
[38]. Nie Y#, Lu W#, Chen D#, Tu H, Guo Z, Zhou X, Li M, Tu S*, Li Y*. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomark Res. 2020 May 27;8:18.（IF=4.866）
[39]. Xie X#, Chen Y#, Hu Y#, He Y, Zhang H, Li Y*. Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma. Mol Cancer Ther. 2019 Dec;18(12):2258-2269.（IF=5.615）
[40]. Xu X#, Sun Q#, Liang X#, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu Y, Tu S*, Li Y*. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Front Immunol. 2019 Nov 12; 10:2664.（IF=5.085）
[41]. Tu S#, Huang R#, Guo Z, Deng L, Song C, Zhou X, Yue C, Zhang L, He Y, Yang J, Liang Z, Du J, Cao P, Li Y, Chang LJ*, Li YH*. Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome. Am J Hematol. 2019 Dec;94(12): E322-E325.（IF=6.973）
[42]. Zhang H#, Zhou L#, Zhou W#, Xie X, Wu M, Chen Y, Hu Y, Du J, He Y, Li Y*. EPS8-mediated regulation of multiple myeloma cell growth and survival. Am J Cancer Res. 2019 Aug 1;9(8):1622-1634.（IF=5.177）
[43]. Li M#, Yang J#, Zhang L#, Tu S, Zhou X, Tan Z, Zhou W*, He Y*, Li Y*. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. J Exp Clin Cancer Res. 2019 May 22;38(1):211.（IF=7.068）
[44]. Wu MR#, Zhang LT#, Zhang HZ, Ning JX, Tu SF, He YJ, Li YH*. CD19 Chimeric Antigen Receptor–Redirected T Cells Combined with Eps8 Peptide Derived Dendritic Cell Vaccine in Leukemia. Cytotherapy. 2019 Jun;21(6):659-670.（IF=4.218）
[45]. Xie X#, Zhou W#, Hu Y, Chen Y, Zhang H, Li Y*. A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. Cell Death Dis. 2018 Mar 7;9(3):379.（IF=6.304）
[46]. Chen Y#, Xie X#, Wu A, Wang L, Hu Y, Zhang H, Li Y*. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. J Exp Clin Cancer Res 2018, 37:12.（IF=7.068）
[47]. Huang R#, Hayashi Y#, Yan X, Bu J, Wang J, Zhang Y, Zhou Y, Tang Y, Wu L, Xu Z, Liu X, Wang Q, Zhou J, Xiao Z, Bridges JP, Marsh RA, Zhang K, Jordan MB, Li Y*, Huang G*. HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis. Haematologica. 2017 Nov. 102(11):1956-1968. (IF=7.9)
[48]. Huang R#, Hayashi Y#, Yan X, Bu J, Wang J, Zhang Y, Zhou Y, Tang Y, Wu L, Xu Z, Liu X, Wang Q, Zhou J, Xiao Z, Bridges JP, Marsh RA, Zhang K, Jordan MB, Li Y*, Huang G*. HIF1A is a critical downstream mediator for hemophagocytic lymphohistiocytosis. Haematologica. 2017 Nov;102(11):1956-1968.（IF=7.116）
[49]. Li D#, Wang L, Hou J, Shen Q, Chen Q, Wang X, Du J, Cai X, Shan Y, Zhang T, Zhou T, Shi X, Li Y*, Zhang H*, Pan G*.Optimized-Approaches for Generation of Integration-free iPSCs from Human Urine-Derived Cells with Small Molecules and Autologous Feeder. Stem Cell Reports. 2016. 6(5):717-728. (IF=5.1)
[50]. Li Y*, Zhou W#, Du J, Jiang C, Xie X, Xue T, He Y*. Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen. Cancer Immunol Immunother 2015; 64(2): 259-269. （IF=5.442）
[51]. Li Y#, Wang S, Scarpellini G, Gunn B, Xin W, Wanda SY, Roland KL, Curtiss RR*. Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc Natl Acad Sci U S A 2009; 106(2):593-598. （IF=9.412）